2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116590
    (±)-Glaziovine 17127-48-9 98%
    (±)-Glaziovine, a proaporphine alkaloid, has anxiolytic activity. (±)-Glaziovine can be used for neuropharmacological research.
    (±)-Glaziovine
  • HY-116606
    LY108742 150196-69-3 98%
    LY108742 is a 5-HT2 receptor antagonist, with IC50 values of 9.3 nM (Rat), 57.2 nM (Pig), 56.8 nM (Monkey).
    LY108742
  • HY-116680
    LY53857 60634-51-7 98%
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves.
    LY53857
  • HY-116685
    AF-CX 1325 88708-96-7 98%
    AF-CX 1325 has strongest antiepileptic effect.
    AF-CX 1325
  • HY-116714
    Cannabigerorcinic acid 69734-83-4 98%
    Cannabigerorcinic acid is structurally similar to known phytocannabinoids.
    Cannabigerorcinic acid
  • HY-116723
    CFMMC 1190598-60-7 98%
    CFMMC is a selective allosteric metabotropic glutamate receptor 1 (mGluR1) antagonist. CFMMC inhibits L-glutamate-induced intracellular Ca2+ mobilization ([Ca2+]i) in Chinese hamster ovary cells expressing recombinant human mGluR1a with an IC50 value of 50 nM. CFMMC is promising for research of various central nervous system disorders, such as schizophrenia, epilepsy, anxiety, pain, cognitive dysfunction and drug abuse.
    CFMMC
  • HY-116850
    Oxagrelate 56611-65-5 98%
    Oxagrelate is a specific inhibitor of cyclic adenosine monophosphate phosphodiesterase and exhibits concentration-dependent inhibition of collagen- and ADP-induced platelet aggregation in vitro.
    Oxagrelate
  • HY-116878
    25B-NBOH hydrochloride 1539266-16-4 98%
    25B-NBOH hydrochloride is structurally categorized as a phenethylamine that displays high affinity for the 5-HT receptors 5-HT2A and 5-HT2C (pKis = 8.3 and 9.4, respectively).
    25B-NBOH hydrochloride
  • HY-117053
    ZM 253270 169340-04-9 98%
    ZM 253270 is a species-selective non-peptide NK-2 receptor (NK-2R) antagonist. ZM 253270 competitively inhibits the binding of [3H]NKA to native or cloned NK-2R from hamster bladder (Ki=2 nM), but has a weaker inhibitory effect (48-fold) on the binding of [3H]NKA to cloned human NK-2R.
    ZM 253270
  • HY-117216
    L-703606 144425-84-3 98%
    L-703606 is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion.
    L-703606
  • HY-117236
    GSI-136 443989-01-3 98%
    GSI-136 is an inhibitor of γ-secretase with an IC50 of 3 nM. GSI-136 can lead to a dose-dependent reduction of Aβ40 levels in diethylamine-extracted brain homogenates of C57BL/6 mice. GSI-136 can be studied in medicinal chemistry and Alzheimer's disease research.
    GSI-136
  • HY-117496
    Ampelopsin A 130608-11-6 98%
    Ampelopsin A is a antifungal agent and can be isolated from the Vitis vinifera canes. Ampelopsin A shows neuroprotective effects.
    Ampelopsin A
  • HY-117512
    UWA-101 hydrochloride 1431520-52-3 98%
    UWA-101 hydrochloride is a selective and non-cytotoxic DAT/SERT inhibitor, with EC50 values of 3.6 µM and 2.3 µM for inhibiting DAT and SERT, respectively. UWA-101 hydrochloride can alleviate the side effects of dopaminergic agents (such as L-DOPA), such as motor disorders, and lacks psychotropic activity. UWA-101 hydrochloride can be used for research on neurodegenerative diseases such as Parkinson's disease.
    UWA-101 hydrochloride
  • HY-117526
    (-)-Mesembrine 24880-43-1
    (-)-Mesembrine is a serotonin transporter (SERT) inhibitor. (-)-Mesembrine inhibits serotonin reuptake. (-)-Mesembrine exerts anxiolytic, mood-enhancing and anti-addictive effects. (-)-Mesembrine is applicable to research on mild-to-moderate depression, anxiety disorders and stress-related conditions.
    (-)-Mesembrine
  • HY-117611
    GAT107 1476807-74-5 98%
    GAT107 (compound 1b) is a potent α7 nAChR ago-PAMs (positive allosteric modulators).
    GAT107
  • HY-117633
    Sultroponium 15130-91-3 98%
    Sultroponium (A118) is an anticholinergic agent.
    Sultroponium
  • HY-117683
    BCTP 464152-46-3 98%
    BCTP is a TRPV1 antagonist. BCTP activated at low pH showed functional antagonist activity against human TRPV1 in CHO cells (IC50=18 nM). BCTP can be used in the study of chronic pain.
    BCTP
  • HY-117754
    PSB-SB1202 1399049-60-5 99.48%
    PSB-SB1202 (Compound 21a) is a phenyl coumarin compound. PSB-SB1202 is a CB1/CB2 agonist with EC50 values of 56 and 14 nM, and Ki values of 32 and 49 nM, respectively.
    PSB-SB1202
  • HY-117786
    Go 7874 153207-86-4 98%
    Go 7874 is a protein kinase C (PKC) inhibitor. Go 7874 mediated neuroprotection against LPS/IFNg-induced neuronal cell death in an immune-mediated neurotoxicity model, not through PKC activity. In contrast, the neuroprotective mechanism of Go 7874 involves inhibition of inducible nitric oxide synthase (iNOS) gene expression, followed by reduced nitric oxide (NO) production.
    Go 7874
  • HY-117804
    8-Br-cADPR 151898-26-9 98%
    8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose), a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR reduces renal damage and the expression of caspase-3 and TRPM2.
    8-Br-cADPR
Cat. No. Product Name / Synonyms Application Reactivity